@article{9984d70e260f4bcb95900c1155a02811,
title = "Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease",
abstract = "Heart failure (HF) and chronic obstructive pulmonary disease (COPD) coincide in a significant number of patients. Recent population-based registries suggest that spirometry is largely underused in patients with HF to diagnose comorbid COPD and that patients with COPD frequently do not receive the recommended beta-blocker (BB) treatment. This state-of-the-art review summarizes: 1) current challenges in the implementation of recommended spirometry for COPD diagnosis in patients with HF; and 2) current underuse and underdosing of BBs in patients with HF and COPD despite guideline recommendations. Open issues in the therapeutic management of patients with HF and COPD are discussed in the third section, including the use of the nonselective BB carvedilol, target BB doses in patients with HF and COPD, BB and bronchodilator management during HF hospitalization with and without COPD exacerbation, and the use of BBs in patients with COPD with right HF or free from cardiovascular disease. The whole scenario described herein advocates for a bipartisan initiative to drive immediate attention to the translation of guideline recommendations into clinical practice for patients with HF with co-occurring COPD. (C) 2019 by the American College of Cardiology Foundation.",
keywords = "ASSOCIATION, BETA-BLOCKERS, EUROPEAN-SOCIETY, EXACERBATIONS, IMPACT, LUNG-DISEASE, MORTALITY, OUTCOMES, RISK, SYSTOLIC DYSFUNCTION, airflow limitation, beta-blockers, chronic obstructive pulmonary disease, heart failure, spirometry, PROGNOSTIC IMPACT, 2013 ACCF/AHA GUIDELINE",
author = "Marco Canepa and Franssen, {Frits M. E.} and Horst Olschewski and Mitja Lainscak and Michael Boehm and Luigi Tavazzi and Stephan Rosenkranz",
note = "Funding Information: Dr. Canepa has received personal fees for lectures and consultancies from Novartis, Pfizer, and Vifor. Dr. Franssen has received personal fees for lectures and consultancies from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Teva, and Verona Pharma; and has received research funding from Novartis and MedImmune. Dr. Tavazzi has received personal fees from Servier (as a trial committee member and member of the Speakers Bureau) and CVIE Therapeutics (as a trial committee member). Dr. B{\"o}hm has received personal fees from Amgen, Bayer, Servier, Medtronic, Boehringer Ingelheim, Vifor, and Bristol-Myers Squibb. Dr. Rosenkranz has received personal fees for lectures and consultancies from Abbot, Actelion, Arena, Bayer, Gilead, GlaxoSmithKline, Merck, Novartis, Pfizer, and United Therapeutics; and has received research grants to his institution from Actelion, Bayer, Novartis, Pfizer, and United Therapeutics. Dr. Olschewski has received personal fees for lectures and consultancies from Actelion, Bayer, Boehringer, Bristol-Myers Squibb, Chiesi, GlaxoSmithKline, Inventiva, Menarini, Merck Sharpe & Dohme, Novartis, Pfizer, and Roche. Dr. Lainscak has received personal fees for lectures and consultancies from AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, and Vifor; and has received research funding from Roche Diagnostics. All fees reported were outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Dr. Canepa has received personal fees for lectures and consultancies from Novartis, Pfizer, and Vifor. Dr. Franssen has received personal fees for lectures and consultancies from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Teva, and Verona Pharma; and has received research funding from Novartis and MedImmune. Dr. Tavazzi has received personal fees from Servier (as a trial committee member and member of the Speakers Bureau) and CVIE Therapeutics (as a trial committee member). Dr. B?hm has received personal fees from Amgen, Bayer, Servier, Medtronic, Boehringer Ingelheim, Vifor, and Bristol-Myers Squibb. Dr. Rosenkranz has received personal fees for lectures and consultancies from Abbot, Actelion, Arena, Bayer, Gilead, GlaxoSmithKline, Merck, Novartis, Pfizer, and United Therapeutics; and has received research grants to his institution from Actelion, Bayer, Novartis, Pfizer, and United Therapeutics. Dr. Olschewski has received personal fees for lectures and consultancies from Actelion, Bayer, Boehringer, Bristol-Myers Squibb, Chiesi, GlaxoSmithKline, Inventiva, Menarini, Merck Sharpe & Dohme, Novartis, Pfizer, and Roche. Dr. Lainscak has received personal fees for lectures and consultancies from AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, and Vifor; and has received research funding from Roche Diagnostics. All fees reported were outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2019 American College of Cardiology Foundation",
year = "2019",
month = oct,
doi = "10.1016/j.jchf.2019.05.009",
language = "English",
volume = "7",
pages = "823--833",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "ELSEVIER SCI LTD",
number = "10",
}